A subpopulation of CD4 cells expressing CD32a is enriched for HIV in patients on antiretroviral therapy.
Antiretroviral therapy (ART) does not cure HIV infection, because the virus persists in a latent reservoir of resting memory CD4 cells that does not appreciably decay over time. Now, researchers have identified a cell surface marker that they propose may identify the HIV reservoir.
To find candidate markers, the investigators first developed an in vitro model by infecting resting CD4 cells with HIV. Of 103 genes that were induced in infected but not in uninfected cells, 16 encoded cell surface markers. Of the markers, HIV infection most specifically induced expression of CD32a, an immunoglobulin G Fc receptor.
The investigators then examined cells from 12 patients receiving ART. CD32a+ cells (0.012% of total CD4 cells) had 1000-fold higher le…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)